1-12 of 12
Amir T. Fathi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome

Clinical Trials & Observations
Courtney D. DiNardo, Gail J. Roboz, Justin M. Watts, Yazan F. Madanat, Gabrielle T. Prince, Praneeth Baratam, Stéphane de Botton, Anthony Stein, James M. Foran, Martha L. Arellano, David A. Sallman, Mohammad Hossain, Dylan M. Marchione, Xiaofei Bai, Prapti A. Patel, Stephanie M. Kapsalis, Guillermo Garcia-Manero, Amir T. Fathi
Journal: Blood Advances
Blood Adv (2024) 8 (15): 4209–4220.
https://doi.org/10.1182/bloodadvances.2023012302
Published: 2024
Includes: Supplemental data
Journal Articles

A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia

Clinical Trials & Observations
Mark Levis, Alexander Perl, Gary Schiller, Amir T. Fathi, Gail Roboz, Eunice S. Wang, Jessica Altman, Trivikram Rajkhowa, Makoto Ando, Takeaki Suzuki, Ruth Ann Subach, Gary Maier, Timothy Madden, Mary Johansen, Kin Cheung, Michael Kurman, Catherine Smith
Journal: Blood Advances
Blood Adv (2024) 8 (10): 2527–2535.
https://doi.org/10.1182/bloodadvances.2023010619
Published: 2024
Includes: Supplemental data
Journal Articles

Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials

Clinical Trials & Observations
Pau Montesinos, Amir T. Fathi, Stéphane de Botton, Eytan M. Stein, Amer M. Zeidan, Yue Zhu, Thomas Prebet, Carlos E. Vigil, Iryna Bluemmert, Xin Yu, Courtney D. DiNardo
Journal: Blood Advances
Blood Adv (2024) 8 (10): 2509–2519.
https://doi.org/10.1182/bloodadvances.2023011914
Published: 2024
Includes: Supplemental data
Journal Articles

Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2 -mutated myeloid malignancies

Clinical Trials & Observations
Amir T. Fathi, Haesook T. Kim, Robert J. Soiffer, Mark J. Levis, Shuli Li, Annette S. Kim, Alice S. Mims, Zachariah DeFilipp, Areej El-Jawahri, Steven L. McAfee, Andrew M. Brunner, Rupa Narayan, Laura W. Knight, Devon Kelley, AJ S. Bottoms, Lindsey H. Perry, Jonathan L. Wahl, Jennifer Brock, Elayne Breton, Vincent T. Ho, Yi-Bin Chen
Journal: Blood Advances
Blood Adv (2022) 6 (22): 5857–5865.
https://doi.org/10.1182/bloodadvances.2022008632
Published: 2022
Includes: Supplemental data
Journal Articles

Coping strategies in patients with acute myeloid leukemia

Hermioni L. Amonoo, Monica H. Bodd, Matthew J. Reynolds, Ashley M. Nelson, Richard Newcomb, Patrick Connor Johnson, Tejaswini M. Dhawale, Rachel Plotke, Lauren Heuer, Sabah Gillani, Daniel Yang, Emma C. Deary, Elizabeth Daskalakis, Lauren Goldschen, Andrew Brunner, Amir T. Fathi, Thomas W. LeBlanc, Areej El-Jawahri
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2435–2442.
https://doi.org/10.1182/bloodadvances.2021005845
Published: 2022
Includes: Supplemental data
Journal Articles

A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML

Clinical Trials & Observations
Emily F. Mason, Olga Pozdnyakova, Mikhail Roshal, Amir T. Fathi, Eytan M. Stein, P. Brent Ferrell, Aaron C. Shaver, Mark Frattini, Hongfang Wang, Lei Hua, Jimmy Mu, Sung Choe, Rengyi Xu, Caroline Almon, Michael Cooper, Richard M. Stone, Robert P. Hasserjian, Michael R. Savona
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2279–2283.
https://doi.org/10.1182/bloodadvances.2020003685
Published: 2021
Includes: Supplemental data
Journal Articles

Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia

Clinical Trials & Observations
Monica Kasbekar, Valentina Nardi, Paola Dal Cin, Andrew M. Brunner, Meghan Burke, Yi-Bin Chen, Christine Connolly, Amir T. Fathi, Julia Foster, Molly Macrae, Steven L. McAfee, Kristin McGregor, Rupa Narayan, Aura Y. Ramos, Tina T. Som, Meghan Vartanian, Robb S. Friedman, Karim A. Benhadji, Gabriela S. Hobbs
Journal: Blood Advances
Blood Adv (2020) 4 (13): 3136–3140.
https://doi.org/10.1182/bloodadvances.2020002308
Published: 2020
Journal Articles

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1 -mutant relapsed or refractory AML

Clinical Trials & Observations
Sung Choe, Hongfang Wang, Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton, Gail J. Roboz, Jessica K. Altman, Alice S. Mims, Justin M. Watts, Daniel A. Pollyea, Amir T. Fathi, Martin S. Tallman, Hagop M. Kantarjian, Richard M. Stone, Lynn Quek, Zenon Konteatis, Lenny Dang, Brandon Nicolay, Parham Nejad, Guowen Liu, Vickie Zhang, Hua Liu, Meredith Goldwasser, Wei Liu, Kevin Marks, Chris Bowden, Scott A. Biller, Eyal C. Attar, Bin Wu
Journal: Blood Advances
Blood Adv (2020) 4 (9): 1894–1905.
https://doi.org/10.1182/bloodadvances.2020001503
Published: 2020
Includes: Supplemental data
Journal Articles

Clinical response to larotrectinib in adult Philadelphia chromosome–like ALL with cryptic ETV6-NTRK3 rearrangement

Clinical Trials & Observations
Valentina Nardi, Nora Ku, Matthew J. Frigault, Adrian M. Dubuc, Harrison Kwei Tsai, Philip C. Amrein, Gabriela S. Hobbs, Andrew M. Brunner, Rupa Narayan, Meghan E. Burke, Julia Foster, Paola Dal Cin, Marcela V. Maus, Amir T. Fathi, Hanno Hock
Journal: Blood Advances
Blood Adv (2020) 4 (1): 106–111.
https://doi.org/10.1182/bloodadvances.2019000769
Published: 2020
Includes: Supplemental data
Journal Articles

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort

Clinical Trials & Observations
Maximilian Stahl, Michelle DeVeaux, Theo de Witte, Judith Neukirchen, Mikkael A. Sekeres, Andrew M. Brunner, Gail J. Roboz, David P. Steensma, Vijaya R. Bhatt, Uwe Platzbecker, Thomas Cluzeau, Pedro H. Prata, Raphaël Itzykson, Pierre Fenaux, Amir T. Fathi, Alexandra Smith, Ulrich Germing, Ellen K. Ritchie, Vivek Verma, Aziz Nazha, Jaroslaw P. Maciejewski, Nikolai A. Podoltsev, Thomas Prebet, Valeria Santini, Steven D. Gore, Rami S. Komrokji, Amer M. Zeidan
Journal: Blood Advances
Blood Adv (2018) 2 (14): 1765–1772.
https://doi.org/10.1182/bloodadvances.2018019414
Published: 2018
Journal Articles

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

Clinical Trials & Observations
Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, Raphael Itzykson, Ellen K. Ritchie, Mikkael A. Sekeres, John D. Barnard, Nikolai A. Podoltsev, Andrew M. Brunner, Rami S. Komrokji, Vijaya R. Bhatt, Aref Al-Kali, Thomas Cluzeau, Valeria Santini, Amir T. Fathi, Gail J. Roboz, Pierre Fenaux, Mark R. Litzow, Sarah Perreault, Tae Kon Kim, Thomas Prebet, Norbert Vey, Vivek Verma, Ulrich Germing, Juan Miguel Bergua, Josefina Serrano, Steven D. Gore, Amer M. Zeidan
Journal: Blood Advances
Blood Adv (2018) 2 (8): 923–932.
https://doi.org/10.1182/bloodadvances.2018016121
Published: 2018
Includes: Supplemental data
Journal Articles

Risk and timing of cardiovascular death among patients with myelodysplastic syndromes

Clinical Trials & Observations
Andrew M. Brunner, Traci M. Blonquist, Gabriela S. Hobbs, Philip C. Amrein, Donna S. Neuberg, David P. Steensma, Gregory A. Abel, Amir T. Fathi
Journal: Blood Advances
Blood Adv (2017) 1 (23): 2032–2040.
https://doi.org/10.1182/bloodadvances.2017010165
Published: 2017
Includes: Supplemental data